ArticleJournal of neuroendocrinology2026
Responses to medical treatment in patients with metastatic unresectable small intestinal neuroendocrine tumors - A single center study of 378 patients.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Small intestinal neuroendocrine tumors (siNET) are rare malignancies, often diagnosed at advanced stages with metastatic spread. While surgery is the only curative treatment, medical therapies, including somatostatin analogues (SSA), peptide receptor radionuclide therapy (PRRT), and other systemic treatments, are essential for disease stabilization. The aim was to assess median progression free survival (mPFS), and prognostic factors for the most frequently used medical treatment modalities in patients with unresectable disease. It was a retrospective single-center cohort study, including 378 patients diagnosed with siNET between 2000 and 2020. The median overall survival (mOS) for the cohort was 97 (95% CI: 83-111) months. Median PFS for octreotide and lanreotide treatment/treated patients (n = 255) was 30 (95% CI: 24-36) months and 5 years PFS was 32%, with no significant difference between the two agents. Risk factors for disease progression included age, Ki-67 index, and gender (female as a protective factor). Median PFS for PRRT (n = 140) was 31 (95% CI: 25-37) months. Thirty-seven patients who had PFS > 18 months after the first 4 cycles received another 2 cycles of PRRT. Median PFS after the first 4 cycles was 37 (95% CI: 30-44) months versus 10 (95% CI: 6-14) months after the 2 additional PRRT cycles. Patients treated with everolimus had a median PFS of 5 (95% CI: 0.3-10) months, and chemotherapy with streptozocin and 5-fluorouracil resulted in a median PFS of 8 (95% CI: 5-11) months. In conclusion, SSA remains the cornerstone of first-line therapy for unresectable siNET, with PRRT offering a valuable alternative for patients with progression on SSA. Re-introduction of PRRT with 2 additional cycles had reduced efficacy compared with the initial treatment. PFS was short in non-somatostatin receptor-based therapies like everolimus and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.